Inflammatory markers and the metabolic syndrome.
Athyros
V G
VG
Elisaf
M
M
Mikhailidis
D P
DP
D000959:Antihypertensive Agents / Q000627:therapeutic use; D000069059:Atorvastatin; D015415:Biomarkers; D002097:C-Reactive Protein / Q000032:analysis*; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D004359:Drug Therapy, Combination; D011345:Fenofibrate / Q000627:therapeutic use; D005340:Fibrinogen / Q000032:analysis*; D006538:Heptanoic Acids / Q000627:therapeutic use; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D007249:Inflammation / Q000097:blood*; D007783:Lactones / Q000627:therapeutic use; D007958:Leukocyte Count; D024821:Metabolic Syndrome / Q000097:blood* / Q000150:complications / Q000188:drug therapy; D008687:Metformin / Q000627:therapeutic use; D000077403:Orlistat; D011446:Prospective Studies; D011758:Pyrroles / Q000627:therapeutic use; D016896:Treatment Outcome
D000959:Antihypertensive Agents; D015415:Biomarkers; D006538:Heptanoic Acids; D000960:Hypolipidemic Agents; D007783:Lactones; D011758:Pyrroles; D005340:Fibrinogen; D002097:C-Reactive Protein; D008687:Metformin; D000077403:Orlistat; D000069059:Atorvastatin; D011345:Fenofibrate